Author:
Yada Koji,Fujitate Natsume,Ogiwara Kenichi,Soeda Tetsuhiro,Kitazawa Takehisa,Nogami Keiji
Funder
Chugai Pharmaceutical Co Ltd
Government of Japan Ministry of Education Culture Sports Science and Technology
Reference35 articles.
1. Risk factors for inhibitor development in hemophilia a;Oldenburg;Haemotologica,2000
2. Treatment regimens with bypassing agents in patients with hemophilia a and inhibitors: a survey from the Italian Association of Hemophilia Centers (AICE);Coppola;Semin. Thromb. Hemost.,2018
3. Recombinant factor VIIa (Novoseven®) in the treatment of internal bleeding in patients with factor VII and IX inhibitors;Lusher;Haemostasis,1996
4. The treatment of factor VIII inhibitors - a general overview;White;Vox Sang.,1996
5. Recombinant factor VIIa: review of efficacy, dosing regimen and safety in patients with congenital and acquired factor VIII or IX inhibitors;Abshire;J. Thromb. Haemost.,2004